相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
Fei Huang et al.
CANCER RESEARCH (2007)
Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy
Raihanatou Diallo-Danebrock et al.
CLINICAL CANCER RESEARCH (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
Molecular subtypes of breast cancer and amplification of topoisomerase IIα:: predictive role in dose intensive adjuvant chemotherapy
J. Hannemann et al.
BRITISH JOURNAL OF CANCER (2006)
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Minna Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
DA Berry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer
S Rodenhuis et al.
ANNALS OF ONCOLOGY (2006)
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95
RL Basset et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients
N Kroger et al.
CLINICAL CANCER RESEARCH (2006)
Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial
M Venturini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer:: results of a multicentre phase III trial
UA Nitz et al.
LANCET (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
The natural history of breast carcinoma in patients with ≥10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy -: A multiinstitutional retrospective study
AJ Montero et al.
CANCER (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13
WP Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy
Y Nieto et al.
CLINICAL CANCER RESEARCH (2004)
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors:: A study of preoperative treatment
M Colleoni et al.
CLINICAL CANCER RESEARCH (2004)
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial
RCF Leonard et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement
IF Faneyte et al.
CLINICAL CANCER RESEARCH (2004)
The role of BRCA1 in the cellular response to chemotherapy
RD Kennedy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes:: First results of a randomized trial
AR Zander et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+breast cancer
Y Nieto et al.
CLINICAL CANCER RESEARCH (2004)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer
S Rodenhuis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
MS Tallman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer
G Somlo et al.
BRITISH JOURNAL OF CANCER (2002)
p53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support
M Hensel et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
SR Lakhani et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
S Paik et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer:: a randomised trial
J Bergh et al.
LANCET (2000)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation
Y Nieto et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
